Kwality Pharmaceuticals Ltd · BSE:KPL
Kwality Pharmaceuticals — Q1 FY27 Earnings Presentation
31 slides from Kwality Pharmaceuticals's earnings presentation, Jun 30, 2026
Slide 1: Q1FY27 Investor Presentation
Kwality Pharmaceuticals Ltd Q1FY27 Investor Presentation
Slide 2: Disclaimer
DISCLAMER Some of the statements made in this presentation are forward-looking statements and are based on the current beliefs, assumptions, expectations, estimates, objectives and projections of the directors and management of Kwality Pharmaceutical Limited about its business, the industry and mark
Slide 3: FY27 Guidance Updated
FY27 Guidance Updated METRICS FY26A PREVIOUS FY27 GUIDANCE UPDATED FY27 GUIDANCE CHANGE / UPDATE (Actual) (vs. Previous Guidance) Raised REVENUE 503 650 700+ Raised Higher growth (₹ Crore) INR 50 Cr+ visibility (+29%) (+39%+) Raised EBITDA 118 176 - 196 189 - 196+ Raised Stronger operating leverage
Slide 4: Decades of Expertise and Manufacturing Excellence
4 Decades of Expertise and Manufacturing Excellence Future Growth: High Margin critical Research + Manufacturing + Quality Excellence Achieved Expertise in Complex Formulation care, Bio-similar and oncology Development & Manufacturing molecules including peptides 01 1,750+ employees including 90+ in
Slide 5: Revenue growth supported by manufacturing scale-up
Revenue growth supported by manufacturing scale-up All values in INR Cr. CAGR : 26% 700+ 503 370 307 251 FY23 FY24 FY25 FY26 FY27E Journey so far… 1983 2018 2020 2022 2023 2024 2025 2026 Company • Manufacturing • Migrated • Established • Established • Initiated • PICs GMP • EUGMP approval for genera
Slide 6: PAT growing ~3x faster than revenue
PAT growing ~3x faster than revenue Revenue Scale Translating into Profit Acceleration Key Levers and their performance over years Key Operational Levers FY23 FY26 Improvement / Status 67 Revenue (₹ Cr) 251 503 ~2x 40 24 503 Cumulative Filings (Nos.) 75 700+ ~1.7x 370 307 200 Capacity Utilisation (O
Slide 7: Leadership backed by Experience
Leadership backed by Experience Ramesh Arora Ajay Arora Aditya Arora Chairman & Managing Director Director Director AREA OF FOCUS AREA OF FOCUS AREA OF FOCUS IT, Software and Legal Raw material procurement and Agreements & Proceedings Quality assurance, Quality infrastructure development control, Re
Slide 8: 4/5 units being EU-GMP approved
4/5 units being EU - GMP approved Unit 6 : Hormones is under construction, expected to commence by H2FY26 Successfully completed 20+ 01 regulatory, customer, and vendor Unit 1 : General Unit 3 : Oncology Unit 5: Biologics audits over the past two years. Proactively upgrades plant 02 practices by ben
Slide 9: Comprehensive Offerings with Advanced Manufacturing Capabilities
Comprehensive Offerings with Advanced Manufacturing Capabilities Amritsar Plant (Campus 1) Himachal plant (Campus 2) Unit 1 Unit 2 Unit 3 Unit 5 Unit 6 Unit 4 (Cephalosporins) (General) (Beta Lactam) (Oncology) (Biologics) (Hormones) Oral Solids - Tab/Capsule, Suppositories Oral Solids - Tab/Capsule
Slide 10: What sets us apart?
What sets us apart? 02 03 01 Diversified portfolio across Open and Flexible Business Model, Globally accredited, strong high entry barrier dosage Powered by in house R&D capabilities manufacturing capabilities forms.. for complex molecule development. 04 05 Wide Presence Healthy Balance sheet provid
Slide 11: 1000+ products across key therapies - Broad Dosage form capabilities
1000+ products across key therapies - Broad Dosage form capabilities Revenue Types Therapies share % Unit wise Revenue Split for Q1FY27 Generals, Beta Lactam, Oncology & Injectables 43% Cephalosporins 63% Generals, Beta Lactam, Oncology & Tablets 40% Cephalosporins Generals, Beta Lactam, Oncology &
Slide 12: Out-Licensing & Supply: Asset-Light Global Market Access
Out-Licensing & Supply : Asset - Light Global Market Access Revenue share Strategic Partnerships Filings 10% 200 175 140 75 90% 100+ clients across LATAM, MENA, Europe, Asia & Africa; FY23 FY24 FY25 FY26 expand via 700+ filings. Outlicensing and Supply CDMO Filings Tie to Moats Leverage achieved Re
Slide 13: CDMO: End-to-End Partnership Driving High-Value Growth
CDMO: End-to-End Partnership Driving High-Value Growth..contd Metric Kwality Stats Benefits Boosting talent, attaining expertise 80 scientists Proves innovation R&D Headcount (DSIR-recognized) muscle 214 Dedicated QA and QC QA & QC team teams function 188 140+; 188+ strength independently across eac
Slide 14: Core Research Initiatives
Applied R&D + Development Engine supporting future CDMO partnerships Core Research Initiatives 01 Biosimilars Development Building end-to-end biologics development and analytical capabilities to support future biosimilar launches and biologics CDMO engagements. Hypothesis driven innovation 02 Enhanc
Slide 15: Differentiated Capabilities
Differentiated Capabilities Lyophilized Injectables Emulsion • Solubility via Freeze - drying Long - acting Technology • Improved Stability Injectables • Fast Absorption • Sustained Drug Release • Low Globule Size • Peptide-based Injections • Low Osmolaity • Polymeric Microspheres Liposomal Pegylate
Slide 16: Export led growth strategy
Export led growth strategy Asia Europe GCC/MENA Operating in 70+ Markets RU/CIS South and Africa Middle East Central America 16
Slide 17: Working Capital Normalizing with Scale, Improving Capital Productivity
Working Capital Normalizing with Scale, Improving Capital Productivity 297 232 231 31.2% 217 208 196 200 189 161 162 22% 22.7% 114 111 19% 15% 11% Cash conversion days Inventory days payable days FY24 FY25 FY26 ROE ROCE FY23 FY24 FY25 FY26 Massive Improvement in cash conversion cycle from 297 days t
Slide 18: Low leverage and strong coverage - significant headroom for capex
Low leverage and strong coverage - significant headroom for capex 0.44 0.43 1.8 0.96 0.41 1.67 0.39 0.88 0.38 1.60 0.38 0.86 Gross Debt/Equity Net Debt/Equity Current ratio Asset turnover FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 9.15 1.79 0.92 1.77 0.74 6.48 0.57 4.68 1.70 Interest coverage Tota
Slide 19: Global Accrediations
Global Accrediations and many more... 19
Slide 20: Q1FY27 Business Updates
Q1FY27 Business Updates Confidential & For Limited Circulation Only
Slide 21: Biologics & Hormones: Building the Next Growth Engines
Biologics & Hormones: Building the Next Growth Engines Strategic capacity additions expand Kwality beyond traditional formulations into high-entry-barrier specialty products. PLACEHOLDER Hormone Facility Photo Development Status Construction Progress Drug Substance + Drug Product capability Pre-clin
Slide 22: Unit 6 - Hormone Facility Update
Unit 6- Hormone Facility Update Construction Update & Commissioning Roadmap Completion Tracker Key Milestones Civil Construction 90% ✓ Construction commenced Q2 FY26 Equipment Procurement 80% ✓ Equipment order placed Q3 FY26 Equipment Installation 60% ○ Major equipment installed Q2 FY27 Utilities &
Slide 23: Q1FY27 Financial Performance
Q1FY27 Financial Performance Confidential & For Limited Circulation Only
Slide 24: Performance drivers for Q1FY27
Performance drivers for Q1FY27 01 Expansion in Regulated Markets 02 Regulatory & Compliance Milestones New registrations secured across LATAM (incl. Mexico, Colombia), MENA, GCC, and EU-GMP certification received for General and Beta Lactam plants — enabling expanded select Asian markets including M
Slide 25: Solid execution reflected in Q1FY27
Solid execution reflected in Q1FY27 Re ve n u e EBITDA a n d Ma rg in s (%) PAT a n d Ma rg in s (%) 162 41 26 112 25 12 2 1 .9 % 2 5 .3 % 11% 16% Q 1FY26 Q 1FY27 Q 1FY26 Q 1FY27 Q 1FY26 Q 1FY27 Re ve n u e EBITDA a n d Ma rg in s (%) PAT a n d Ma rg in s (%) 158 162 39 41 26 25 2 4 .8 % 2 5 .3 % 16
Slide 26: Profit and Loss Statement - Q1FY27
Profit and Loss Statement - Q1FY27 Particulars Q1FY27 Q4FY26 QoQ Q1FY26 YoY Revenue from operations (Net) 162.4 157.1 3.4% 111.5 45.7% (a) Cost of materials consumed 85.3 79.7 7.0% 49.9 70.9% (b) Purchases of stock-in-trade 0.5 6.0 -91.7% 7.9 -93.7% (c) Changes in inventories of finished goods work
Slide 27: Historical Statement of Profit & Loss
Historical Statement of Profit & Loss Particulars FY23 FY24 FY25 FY26 Revenue from operations (Net) 251 307 370 503 (a) Cost of materials consumed 113 154 165 241 (b) Purchases of stock-in-trade 0 1 16 17 (c) Changes in inventories of finished goods work - in - progress and stock - in - trade -3 -1
Slide 28: Balance Sheet
Balance Sheet Particulars (In INR Cr.) FY23 FY24 FY25 FY26 Particulars (In crs) FY23 FY24 FY25 FY26 ASSETS 354 394 447 592 EQUITY & LIABILITIES 354 394 447 592 Equity Non-current assets 146 152 163 186 Share Capital 10 10 10 10 Other Equity 190 214 254 322 Property Plant & Equipment 120 139 144 150
Slide 29: Cash Flow Statement
Cash Flow Statement Particulars FY23 FY24 FY25 FY26 Cashflow from Operating Activities 41.38 42.98 52.72 16.59 Cashflow from Investing Activities (48.44) (26.39) (28.52) (34.90) Cashflow from Financing Activities 0.99 (17.39) (14.44) 7.03 Cash and Cash Equivalents as at end of period/Year 3.07 2
Slide 30: Scaling to next orbit: INR 1000+ Cr FY29 revenue milestone
Scaling to next orbit : INR 1000+ Cr FY29 revenue milestone Expanding to high margin specialty platforms Commercialize its first biologic, Erythropoietin, in H1 of the next financial year, while continuing to build its presence in complex and niche injectable manufacturing. Expected Outcome Margins
Slide 31: Thank You
THANK YOU Kwality Pharmaceuticals Ltd. Head Office Address : 6th Milestone, Majitha Road, Amritsar-143601, Punjab, India Company Contact: Ujjval Seth Ujjvalseth@kwalitypharma.com Investor Relations Contact: Go India Advisors Soumya Chhajed soumya@goindiaadvisors.com
Kwality Pharmaceuticals — Q1 FY27 Earnings Presentation on 6ix